Senzime has secured a three-year GPO contract with one of the largest hospital and managed care organizations in the US for the TetraGraph monitoring system. The sole source agreement includes TetraGraph as the only stand-alone EMG-based quantitative neuromuscular monitor available on contract, giving access to over 40 hospitals that serve over 12.5 million patients annually across 11 US states. Every year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions.

These medications paralyze muscles required for breathing; hence, accurate monitoring during surgery to secure each patient's individual dose is paramount for a safe and timely recovery. Senzime's TetraGraph is a quantitative train-of-four (TOF) neuromuscular monitoring system used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology helps anesthesiologists accurately select the right dose of neuromuscular blocking drugs and their antagonists allowing for patients to safely recover following surgery.